Anaphylaxie nach gleichzeitiger Impfung gegen Masern, Mumps, Röteln und Frühsommer-Meningoenzephalitis aufgrund einer Gelatineallergie

Kamin, Wolfgang; Staubach, P; Klär-Hlawatsch, B.; Erdnüss, F; Knuf, M

doi:10.1055/s-2005-836609

Cited by 18 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 , 4 Several BoNT-A formulations are available and the number of preparations is likely to increase. 4 , 8 , 9 These are not, however, interchangeable based on dose units or, potentially, immunogenicity. 4 Partly because of inappropriate dose comparisons between the various formulations and also marketing campaigns, numerous myths and misconceptions about the use of BoNT-A for aesthetic indications have arisen that are not supported by the evidence.…”

Section: Discussionmentioning

confidence: 99%

“…The presence of gelatin may be unacceptable to some cultural and religious groups and, in addition, gelatin confers an increased risk of allergic reactions, including anaphylactic shock. 9 , 48…”

Section: Myth 4: Neutralizing Antibodies Are An Important Determinantmentioning

confidence: 99%

“…BoNT-B is also available as rimabotulinumtoxinB (Myobloc/Neurobloc), although this is not currently approved for aesthetic indications. 4 , 8 , 9 …”

mentioning

confidence: 99%

See 2 more Smart Citations

Botulinum Toxin in Aesthetic Medicine: Myths and Realities

Dover

Monheit²,

Greener³

et al. 2018

Dermatol Surg

View full text Add to dashboard Cite

BACKGROUNDSeveral formulations of Botulinum toxin serotype A (BoNT-A) for aesthetic indications are available, with numbers likely to increase. Preparations are not interchangeable, based on dose unit comparisons.OBJECTIVENumerous myths and misconceptions regarding the use of BoNT-A for aesthetic indications have arisen, which this review aims to lay to rest.MATERIALS AND METHODSThis review assesses evidence for and against each of the most common myths regarding BoNT use in aesthetics.RESULTSBoNT-A neurotoxin/protein complexes are irrelevant to the toxin's therapeutic/aesthetic indications. BoNT-A neurotoxin/protein complexes do not influence movement from injection site or immunogenicity. Any relationship between neutralizing antibody formation and clinical response is complex and clinicians should consider other factors that may induce an apparent loss of clinical response. Diffusion appears predominately, perhaps exclusively, dose dependent. Careful placement and correct dosing optimizes likelihood of good outcomes. Manufacturers recommend reconstitution of products with sterile nonpreserved saline. However, compelling evidence suggests that reconstitution using preserved saline dramatically improves patient comfort without compromising efficacy. Several post-treatment instructions/restrictions are widely used despite the lack of evidence, but muscle activity after injection may be beneficial. Cooling the treatment area might hinder BoNT-A translocation and should probably be abandoned.CONCLUSIONThe existing evidence suggests that experienced users should achieve equivalent results regardless of BoNT-A formulation, but additional, well-designed, adequately powered, controlled randomized studies should be performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Myth 4: Neutralizing Antibodies Are An Important Determinantmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum Toxin in Aesthetic Medicine: Myths and Realities

Dover

Monheit²,

Greener³

et al. 2018

Dermatol Surg

View full text Add to dashboard Cite

show abstract

“…In addition, gelatine confers an increased risk of allergic reactions, including anaphylactic shock. 57 One patient has been reported to have developed urticarial plaques proximal to the injection site when this product was used, emphasizing the immunogenic potential. 58 Most use is uneventful.…”

Section: Future Developmentsmentioning

confidence: 99%

AbobotulinumtoxinA: A 25-Year History

Monheit

Pickett

2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

During the late 1960s and early 1970s, Alan Scott showed that intramuscular injections of botulinum toxin (BoNT) corrected nonaccommodative strabismus without resorting to surgery. The UK doctors who trained with Scott soon realized the significant potential offered by BoNT type A as a therapeutic option for several difficult-to-treat diseases. This led to a collaboration between these pioneering clinicians and the Centre for Applied Microbiology and Research at Porton Down, United Kingdom, and, in turn, to the development and commercialization of abobotulinumtoxinA as Dysport (Dystonia/Porton Down; Ipsen Biopharm Ltd., Wrexham, UK). Dysport was approved in Europe for the treatment of specific dystonias in December 1990 and now has marketing authorizations in 75 countries. Since then, the use of BoNT in therapeutic and aesthetic indications has grown year-on-year, and continues to expand well beyond Scott’s initial aim. For example, ongoing trials are assessing potential new indications for BoNT-A, including acne and psoriasis. Furthermore, a growing number of other BoNT products, often termed “biosimilars,” together with innovative formulations of well-established BoNT types, are likely to reach the market over the next few years. This review focuses on the history of Dysport to mark the 25th anniversary of its first launch in the United Kingdom.

show abstract

“…For example children with ALL have a 10-fold in creased risk for invasive pneumococcal infection, mainly during maintenance therapy [24] , that might be abolished by early effective vaccination with a conjugated vaccine. On the other hand, allergic or hyperergic reactions after vaccination in patients after chemotherapy occur more often in patients under oncologic therapy than in healthy children [15] .…”

Section: Statisticsmentioning

confidence: 99%

Diphtheria (D) and Tetanus (T) Antibody Values in Children with Acute Lymphoblastic Leukaemia (ALL) after Treatment According to Co-ALL 05/92

Calaminus¹,

Hense²,

Laws³

et al. 2007

Klin Padiatr

View full text Add to dashboard Cite

In children and adolescents with ALL after therapy antibody levels of D and T are dependent on treatment intensity. Revaccination leads to an adequate immunological answer against T in most patients , which is not the case for the diphtheria vaccination. Prospective multicenter trials starting together with the ALL-treatment should be able to gain more information about the behavior of antibody levels and the risk of infection from vaccine-preventable disease in immunocompromised patients and thus lead to standardized vaccination guidelines such as immunization with conjugate vaccines already during maintenance treatment.

show abstract

Anaphylaxie nach gleichzeitiger Impfung gegen Masern, Mumps, Röteln und Frühsommer-Meningoenzephalitis aufgrund einer Gelatineallergie

Cited by 18 publications

References 0 publications

Botulinum Toxin in Aesthetic Medicine: Myths and Realities

Botulinum Toxin in Aesthetic Medicine: Myths and Realities

AbobotulinumtoxinA: A 25-Year History

Diphtheria (D) and Tetanus (T) Antibody Values in Children with Acute Lymphoblastic Leukaemia (ALL) after Treatment According to Co-ALL 05/92

Contact Info

Product

Resources

About